Stratification of Homologous Recombination Deficiency-Negative High-Grade Ovarian Cancer by the Type of Peritoneal Spread into Two Groups with Distinct Survival Outcomes
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.In high-grade ovarian cancer, tumor spread patterns, not homologous recombination deficiency (HRD), better predict survival. Miliary spread indicates poor prognosis, while non-miliary spread shows better outcomes, regardless of HRD status.
Area Of Science
- Oncology
- Genomics
- Cancer Biology
Background
- Homologous recombination deficiency (HRD) is a key marker in high-grade ovarian cancer (HGOC), predicting response to PARP inhibitors and platinum therapy.
- Tumor spread patterns, specifically miliary vs. non-miliary, also significantly impact HGOC treatment response and patient survival.
Purpose Of The Study
- To develop and validate a novel HRD assessment method, the predictive-value integrated genomic instability score (PIGIS).
- To investigate the correlation between tumor spread type and HRD status in HGOC.
- To determine the impact of tumor spread and HRD status on patient survival.
Main Methods
- Adapted existing HRD assessment methods to create PIGIS.
- Validated PIGIS in 122 HGOC patient samples.
- Analyzed the relationship between tumor spread type, HRD status, and survival outcomes.
Main Results
- PIGIS effectively differentiates HRD-positive from HRD-negative samples.
- Miliary tumor spread, associated with HRD-negative status, showed poor prognosis (PFS 15.6 months, OS 3.9 years).
- HRD-negative non-miliary spread and HRD-positive tumors had similar, significantly better prognoses (PFS ~35 months, OS ~8.9 years).
Conclusions
- Tumor spread type and cytoreduction efficiency appear to be superior survival predictors over HRD status in a PARPi-naïve HGOC cohort.
- HRD status might serve as an indirect marker for tumor spread and cytoreduction efficiency.
- Further research is needed to confirm if these findings extend to PARPi sensitivity.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...